![]() |
|||||||
|
Fusion Protein:ATXN10-FBLN1 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: ATXN10-FBLN1 | FusionPDB ID: 8370 | FusionGDB2.0 ID: 8370 | Hgene | Tgene | Gene symbol | ATXN10 | FBLN1 | Gene ID | 25814 | 2192 |
Gene name | ataxin 10 | fibulin 1 | |
Synonyms | E46L|HUMEEP|SCA10 | FBLN|FIBL1 | |
Cytomap | 22q13.31 | 22q13.31 | |
Type of gene | protein-coding | protein-coding | |
Description | ataxin-10brain protein E46 homologspinocerebellar ataxia type 10 protein | fibulin-1 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q9UBB4 Main function of 5'-partner protein: FUNCTION: Necessary for the survival of cerebellar neurons. Induces neuritogenesis by activating the Ras-MAP kinase pathway. May play a role in the maintenance of a critical intracellular glycosylation level and homeostasis. {ECO:0000250}. | P23142 Main function of 5'-partner protein: FUNCTION: Incorporated into fibronectin-containing matrix fibers. May play a role in cell adhesion and migration along protein fibers within the extracellular matrix (ECM). Could be important for certain developmental processes and contribute to the supramolecular organization of ECM architecture, in particular to those of basement membranes. Has been implicated in a role in cellular transformation and tumor invasion, it appears to be a tumor suppressor. May play a role in haemostasis and thrombosis owing to its ability to bind fibrinogen and incorporate into clots. Could play a significant role in modulating the neurotrophic activities of APP, particularly soluble APP. {ECO:0000269|PubMed:11792823, ECO:0000269|PubMed:9393974, ECO:0000269|PubMed:9466671}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000498009, ENST00000252934, ENST00000381061, ENST00000402380, | ENST00000262722, ENST00000327858, ENST00000340923, ENST00000348697, ENST00000402984, ENST00000442170, ENST00000476366, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 16 X 12 X 11=2112 | 22 X 22 X 9=4356 |
# samples | 19 | 27 | |
** MAII score | log2(19/2112*10)=-3.47453851102751 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(27/4356*10)=-4.01197264166608 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: ATXN10 [Title/Abstract] AND FBLN1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: ATXN10 [Title/Abstract] AND FBLN1 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ATXN10(46088958)-FBLN1(45996187), # samples:2 FBLN1(45914667)-ATXN10(46134611), # samples:1 FBLN1(45931217)-ATXN10(46202839), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | ATXN10-FBLN1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN10-FBLN1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN10-FBLN1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN10-FBLN1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN10-FBLN1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. ATXN10-FBLN1 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. FBLN1-ATXN10 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. FBLN1-ATXN10 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ATXN10 | GO:0031175 | neuron projection development | 16498633 |
Tgene | FBLN1 | GO:0001933 | negative regulation of protein phosphorylation | 11792823 |
Tgene | FBLN1 | GO:0007162 | negative regulation of cell adhesion | 11792823 |
Tgene | FBLN1 | GO:0007229 | integrin-mediated signaling pathway | 11792823 |
Tgene | FBLN1 | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 11792823 |
Tgene | FBLN1 | GO:0072378 | blood coagulation, fibrin clot formation | 7642629 |
Tgene | FBLN1 | GO:1900025 | negative regulation of substrate adhesion-dependent cell spreading | 11792823 |
Tgene | FBLN1 | GO:2000146 | negative regulation of cell motility | 11792823 |
Tgene | FBLN1 | GO:2000647 | negative regulation of stem cell proliferation | 11238726 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:46088958/chr22:45996187) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000348697 | FBLN1 | chr22 | 45914562 | + | 3186 | 465 | 266 | 2497 | 743 |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000402984 | FBLN1 | chr22 | 45914562 | + | 2638 | 465 | 266 | 2551 | 761 |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000262722 | FBLN1 | chr22 | 45914562 | + | 2534 | 465 | 266 | 2437 | 723 |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000327858 | FBLN1 | chr22 | 45914562 | + | 3187 | 465 | 266 | 2497 | 743 |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000442170 | FBLN1 | chr22 | 45914562 | + | 2901 | 465 | 266 | 2191 | 641 |
ENST00000381061 | ATXN10 | chr22 | 46088958 | + | ENST00000340923 | FBLN1 | chr22 | 45914562 | + | 2724 | 465 | 266 | 2086 | 606 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000348697 | FBLN1 | chr22 | 45914562 | + | 3377 | 656 | 265 | 2688 | 807 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000402984 | FBLN1 | chr22 | 45914562 | + | 2829 | 656 | 265 | 2742 | 825 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000262722 | FBLN1 | chr22 | 45914562 | + | 2725 | 656 | 265 | 2628 | 787 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000327858 | FBLN1 | chr22 | 45914562 | + | 3378 | 656 | 265 | 2688 | 807 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000442170 | FBLN1 | chr22 | 45914562 | + | 3092 | 656 | 265 | 2382 | 705 |
ENST00000252934 | ATXN10 | chr22 | 46088958 | + | ENST00000340923 | FBLN1 | chr22 | 45914562 | + | 2915 | 656 | 265 | 2277 | 670 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000381061 | ENST00000348697 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.008751115 | 0.99124885 |
ENST00000381061 | ENST00000402984 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.012989094 | 0.98701096 |
ENST00000381061 | ENST00000262722 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.016154366 | 0.9838456 |
ENST00000381061 | ENST00000327858 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.009039113 | 0.9909609 |
ENST00000381061 | ENST00000442170 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.018976394 | 0.98102355 |
ENST00000381061 | ENST00000340923 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.018633857 | 0.98136616 |
ENST00000252934 | ENST00000348697 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.007049251 | 0.9929508 |
ENST00000252934 | ENST00000402984 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.007884854 | 0.9921151 |
ENST00000252934 | ENST00000262722 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.012414482 | 0.98758554 |
ENST00000252934 | ENST00000327858 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.00733078 | 0.9926692 |
ENST00000252934 | ENST00000442170 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.016162122 | 0.98383784 |
ENST00000252934 | ENST00000340923 | ATXN10 | chr22 | 46088958 | + | FBLN1 | chr22 | 45914562 | + | 0.017211815 | 0.98278815 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for ATXN10-FBLN1 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
ATXN10 | chr22 | 46088958 | FBLN1 | chr22 | 45914562 | 465 | 65 | LFRELRVEQESLLTVDADVLLEACCA |
ATXN10 | chr22 | 46088958 | FBLN1 | chr22 | 45914562 | 656 | 129 | LFRELRVEQESLLTVDADVLLEACCA |
Top |
Potential FusionNeoAntigen Information of ATXN10-FBLN1 in HLA I |
![]() |
ATXN10-FBLN1_46088958_45914562.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B45:01 | VEQESLLTV | 0.9983 | 0.8565 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:02 | VEQESLLTV | 0.9975 | 0.7701 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B13:02 | VEQESLLTV | 0.9969 | 0.7537 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B45:01 | QESLLTVDA | 0.9885 | 0.8339 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B13:01 | VEQESLLTV | 0.9785 | 0.9765 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:02 | QESLLTVDA | 0.9765 | 0.7417 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B47:01 | VEQESLLTV | 0.8275 | 0.6218 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B18:01 | VEQESLLTV | 0.7557 | 0.9188 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:01 | VEQESLLTV | 0.5468 | 0.8927 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:01 | VEQESLLTV | 0.5361 | 0.8214 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:01 | QESLLTVDA | 0.5232 | 0.904 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:01 | QESLLTVDA | 0.3236 | 0.8828 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B52:01 | VEQESLLTV | 0.1433 | 0.9873 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B39:13 | VEQESLLTV | 0.1008 | 0.9733 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:21 | RVEQESLLTV | 0.8885 | 0.6313 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:01 | RVEQESLLTV | 0.7523 | 0.8814 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:01 | RVEQESLLTV | 0.6859 | 0.8586 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B45:01 | RVEQESLLTV | 0.6508 | 0.8347 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B13:02 | RVEQESLLTV | 0.5663 | 0.8559 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B45:01 | VEQESLLTVDA | 0.9967 | 0.7227 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:02 | VEQESLLTVDA | 0.9879 | 0.6037 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:67 | SLLTVDADVLL | 0.9843 | 0.5639 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:30 | SLLTVDADVLL | 0.9843 | 0.5639 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:24 | SLLTVDADVLL | 0.9843 | 0.5639 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:60 | SLLTVDADVLL | 0.9838 | 0.5007 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:04 | SLLTVDADVLL | 0.9835 | 0.54 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:16 | SLLTVDADVLL | 0.9818 | 0.511 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:01 | VEQESLLTVDA | 0.9803 | 0.7953 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:01 | VEQESLLTVDA | 0.9772 | 0.8155 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:29 | SLLTVDADVLL | 0.8993 | 0.5645 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:20 | SLLTVDADVLL | 0.889 | 0.5713 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B51:07 | EQESLLTV | 0.9734 | 0.9569 | 7 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:06 | VEQESLLTV | 0.9993 | 0.6663 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-C03:07 | LTVDADVLL | 0.9983 | 0.9476 | 12 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B44:10 | VEQESLLTV | 0.9688 | 0.5702 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:03 | VEQESLLTV | 0.9663 | 0.5008 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:06 | QESLLTVDA | 0.9319 | 0.7577 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B39:08 | VEQESLLTV | 0.4399 | 0.8648 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B51:07 | VEQESLLTV | 0.0926 | 0.9831 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:06 | RVEQESLLTV | 0.8916 | 0.7519 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:06 | VEQESLLTVDA | 0.9984 | 0.7055 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:01 | SLLTVDADVLL | 0.9843 | 0.5639 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:04 | VEQESLLTV | 0.9889 | 0.7987 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-C03:06 | LTVDADVLL | 0.9794 | 0.9848 | 12 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B18:05 | VEQESLLTV | 0.7557 | 0.9188 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B18:06 | VEQESLLTV | 0.7416 | 0.9275 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-C17:01 | LTVDADVLL | 0.656 | 0.913 | 12 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B18:03 | VEQESLLTV | 0.6438 | 0.9112 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:03 | VEQESLLTV | 0.6388 | 0.5461 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:05 | VEQESLLTV | 0.5361 | 0.8214 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:04 | VEQESLLTV | 0.5361 | 0.8214 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B18:11 | VEQESLLTV | 0.3657 | 0.8959 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:04 | QESLLTVDA | 0.3236 | 0.8828 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:05 | QESLLTVDA | 0.3236 | 0.8828 | 8 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B39:02 | VEQESLLTV | 0.1183 | 0.9733 | 6 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:06 | RVEQESLLTV | 0.8885 | 0.6313 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:04 | RVEQESLLTV | 0.7523 | 0.8814 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:05 | RVEQESLLTV | 0.7523 | 0.8814 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B41:03 | RVEQESLLTV | 0.4468 | 0.5595 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B40:04 | RVEQESLLTV | 0.3702 | 0.8306 | 5 | 15 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-A02:14 | SLLTVDADVLL | 0.9822 | 0.6097 | 10 | 21 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:05 | VEQESLLTVDA | 0.9803 | 0.7953 | 6 | 17 |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 | HLA-B50:04 | VEQESLLTVDA | 0.9803 | 0.7953 | 6 | 17 |
Top |
Potential FusionNeoAntigen Information of ATXN10-FBLN1 in HLA II |
![]() |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of ATXN10-FBLN1 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
9901 | VEQESLLTVDADVL | ATXN10 | FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 656 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATXN10-FBLN1 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 9901 | VEQESLLTVDADVL | -5.34942 | -6.38472 |
HLA-B14:02 | 3BVN | 9901 | VEQESLLTVDADVL | -5.0153 | -5.1287 |
HLA-B52:01 | 3W39 | 9901 | VEQESLLTVDADVL | -7.47358 | -7.58698 |
HLA-B52:01 | 3W39 | 9901 | VEQESLLTVDADVL | -4.5023 | -5.5376 |
HLA-A11:01 | 4UQ2 | 9901 | VEQESLLTVDADVL | -7.49832 | -7.61172 |
HLA-A24:02 | 5HGA | 9901 | VEQESLLTVDADVL | -8.30687 | -8.42027 |
HLA-A24:02 | 5HGA | 9901 | VEQESLLTVDADVL | -5.37786 | -6.41316 |
HLA-B27:05 | 6PYJ | 9901 | VEQESLLTVDADVL | -6.81213 | -7.84743 |
HLA-B44:05 | 3DX8 | 9901 | VEQESLLTVDADVL | -9.00919 | -9.12259 |
HLA-B44:05 | 3DX8 | 9901 | VEQESLLTVDADVL | -3.81824 | -4.85354 |
Top |
Vaccine Design for the FusionNeoAntigens of ATXN10-FBLN1 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 10 | 21 | SLLTVDADVLL | TGTTGACAGTGGACGCGGATGTCCTCCTGGAGG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 12 | 21 | LTVDADVLL | CAGTGGACGCGGATGTCCTCCTGGAGG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 5 | 15 | RVEQESLLTV | TGGAACAGGAATCTCTGTTGACAGTGGACG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 6 | 15 | VEQESLLTV | AACAGGAATCTCTGTTGACAGTGGACG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 6 | 17 | VEQESLLTVDA | AACAGGAATCTCTGTTGACAGTGGACGCGGATG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 7 | 15 | EQESLLTV | AGGAATCTCTGTTGACAGTGGACG |
ATXN10-FBLN1 | chr22 | 46088958 | chr22 | 45914562 | 8 | 17 | QESLLTVDA | AATCTCTGTTGACAGTGGACGCGGATG |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of ATXN10-FBLN1 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
UCEC | ATXN10-FBLN1 | chr22 | 46088958 | ENST00000252934 | chr22 | 45914562 | ENST00000262722 | TCGA-AX-A1CC-01A |
Top |
Potential target of CAR-T therapy development for ATXN10-FBLN1 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to ATXN10-FBLN1 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ATXN10-FBLN1 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |